Text Size

Three New Methods for Diagnosing Pancreas Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of Copenhagen.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Copenhagen
ClinicalTrials.gov Identifier:
NCT00259532
First received: November 25, 2005
Last updated: February 25, 2009
Last verified: February 2009
History of Changes
  Purpose

The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.


Condition Intervention
Pancreas Cancer
 Procedure: Ultrasound and contrast agent

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Copenhagen:

Estimated Enrollment: 80
Study Start Date: February 2005
Estimated Study Completion Date: January 2009
Intervention Details:
    Procedure: Ultrasound and contrast agent
    contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspicion of cancer of the pancreas
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00259532

Contacts
Contact: Hanne S Grossjohann, MD +45 35453419 hannesonder@dadlnet.dk

Locations
Denmark
Copenhagen University Hospital Recruiting
Copenhagen, Denmark, 2100
Contact: Hanne S Grossjohann, MD     +45 35453419     hannesonder@dadlnet.dk    
Principal Investigator: Hanne S Grossjohann, MD            
Sponsors and Collaborators
University of Copenhagen
Investigators
Principal Investigator: Michael B Nielsen, DMSc Department of Radiology, Section of Ultrasound
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00259532     History of Changes
Other Study ID Numbers: (KF) 01 268342
Study First Received: November 25, 2005
Last Updated: February 25, 2009
Health Authority: Denmark: Ethics Committee

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
 Pancreatic Diseases
Endocrine System Diseases
Pancrelipase
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013